AIMS: Safety concerns regarding the use of echo-contrast agents during baseline and SE in patients with recent chest pain have been raised. The purpose of the present study was to provide evidence regarding the safety of flash-replenishment contrast dipyridamole-atropine echocardiography (DASE) in such patients. METHODS AND RESULTS: Five hundred consecutive individuals who presented to the Emergency Department with chest pain, normal electrocardiograms (ECG) and troponin I were selected based on a less than 5 days interval between chest pain episode and performance of contrast flash-replenishment DASE. Analysis of myocardial perfusion with SonoVue infusion after dipyridamole was routinely added on top of standard wall motion assessment during DASE. Adverse events (AEs) were reported according to standardized terminology and then compared with a historical control group in which contrast was not used. No deaths, myocardial infarctions, sustained arrhythmias, or any other life-threatening events were observed. Adverse events were not significantly different between the study group and the control group. In the selected subgroup of patients (n = 149) who underwent coronary angiography, accuracy of DASE with additional perfusion assessment was higher (88%, 95% C.I. 83-93%) than without (72%, 95% C.I. 65-79%). CONCLUSION: DASE with SonoVue infusion for myocardial perfusion assessment was exceptionally safe even when routinely performed within the first 5 days following a chest pain episode of undetermined origin in subjects without ECG and troponin abnormalities.
AIMS: Safety concerns regarding the use of echo-contrast agents during baseline and SE in patients with recent chest pain have been raised. The purpose of the present study was to provide evidence regarding the safety of flash-replenishment contrast dipyridamole-atropine echocardiography (DASE) in such patients. METHODS AND RESULTS: Five hundred consecutive individuals who presented to the Emergency Department with chest pain, normal electrocardiograms (ECG) and troponin I were selected based on a less than 5 days interval between chest pain episode and performance of contrast flash-replenishment DASE. Analysis of myocardial perfusion with SonoVue infusion after dipyridamole was routinely added on top of standard wall motion assessment during DASE. Adverse events (AEs) were reported according to standardized terminology and then compared with a historical control group in which contrast was not used. No deaths, myocardial infarctions, sustained arrhythmias, or any other life-threatening events were observed. Adverse events were not significantly different between the study group and the control group. In the selected subgroup of patients (n = 149) who underwent coronary angiography, accuracy of DASE with additional perfusion assessment was higher (88%, 95% C.I. 83-93%) than without (72%, 95% C.I. 65-79%). CONCLUSION: DASE with SonoVue infusion for myocardial perfusion assessment was exceptionally safe even when routinely performed within the first 5 days following a chest pain episode of undetermined origin in subjects without ECG and troponin abnormalities.
Authors: Sahar S Abdelmoneim; Matthew W Martinez; Sunil V Mankad; Mathieu Bernier; Abhijeet Dhoble; Patricia A Pellikka; Krishnaswamy Chandrasekaran; Jae K Oh; Sharon L Mulvagh Journal: Heart Vessels Date: 2014-01-10 Impact factor: 2.037
Authors: Aneta D Petelska; Jacek R Janica; Joanna Kotynska; Urszula Łebkowska; Zbigniew A Figaszewski Journal: J Membr Biol Date: 2011-11-24 Impact factor: 1.843